Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes the immune system to attack the body’s own joint tissues, leading to inflammation, pain, and eventually joint destruction. If you’re trying to sort true statements from false ones, the key facts center on its symmetrical pattern, its systemic nature, its autoimmune origin, and the way it differs from osteoarthritis. Here’s what is definitively true about RA, broken down by category.
RA Affects Joints Symmetrically
One of the most frequently tested and consistently true statements about RA is that it typically affects joints on both sides of the body in a symmetrical pattern. If your left wrist is inflamed, your right wrist is likely inflamed too. This is a hallmark that distinguishes it from osteoarthritis, which tends to affect weight-bearing joints like knees and hips and is commonly asymmetrical. RA most often targets the small joints of the hands and feet first, though larger joints can become involved as the disease progresses.
It Is an Autoimmune Disease, Not Wear-and-Tear
RA is fundamentally different from osteoarthritis. Osteoarthritis results from mechanical wear on cartilage over time. RA, by contrast, is driven by an immune system malfunction: the body’s own immune cells attack the synovial membrane that lines the joints. This triggers chronic inflammation, overgrowth of the synovial tissue (called a pannus), and eventually destruction of both cartilage and bone. The pannus is a mass of thickened, inflamed tissue that invades the joint surface, producing enzymes that break down cartilage at its edges and allowing bone-resorbing cells to eat into the underlying bone.
Three interacting processes drive joint damage in RA: chronic inflammation, overgrowth of the synovial lining, and increased activity of bone-destroying cells. This is why early treatment matters so much. The damage is not simply from “swelling” but from an aggressive biological process that erodes the joint from the inside.
Morning Stiffness Lasts Over an Hour
Morning stiffness is a feature of many types of arthritis, but the duration is a reliable clue. In RA, morning stiffness typically persists for more than one hour and often lasts several hours. In osteoarthritis, stiffness usually resolves within a few minutes. The length of morning stiffness in RA also serves as a gauge of how active the inflammation is on a given day. Similar stiffness can return after long periods of sitting or inactivity.
Women Are Affected Two to Three Times More Often
RA is not equally distributed between sexes. About 70% of people living with RA are women, making females two to three times more likely to develop the disease than males. As of 2019, roughly 18 million people worldwide were living with RA, according to the World Health Organization, and 55% of them were older than 55. While RA can develop at any age, onset most commonly occurs in middle adulthood.
RA Affects More Than Just Joints
A true and often surprising fact about RA is that it is a systemic disease, meaning it can damage organs far beyond the joints. The inflammation that drives RA can involve the skin, eyes, heart, lungs, kidneys, nervous system, and gastrointestinal tract.
Some of the most common extra-joint effects include:
- Rheumatoid nodules: firm lumps under the skin, found in about 20% of RA patients, making them the most frequent skin manifestation.
- Lung involvement: pleural disease (inflammation of the tissue lining the lungs) is common but usually produces no symptoms. Autopsy studies have found evidence of pleural involvement in 50% of RA patients, though only about 10% are ever diagnosed during life.
- Heart disease: RA increases the risk of atherosclerosis (thickening of artery walls) and heart attacks. Inflammation of the sac around the heart (pericarditis) is the most common cardiac complication, and autopsy studies show pericardial inflammation in about 50% of patients, most of whom never had symptoms.
- Anemia and dry eyes: chronic inflammation frequently causes anemia, and a condition called Sjögren’s syndrome (severe dryness of the eyes and mouth) occurs in 6 to 10% of patients early in the disease.
These extra-joint manifestations are linked to worse functional outcomes and higher mortality, which is why RA is treated as a whole-body condition rather than simply a joint problem.
Genetics Play a Major Role
RA has a strong genetic component. The single most significant genetic risk factor involves a group of immune system genes called HLA, specifically certain variations of the HLA-DRB1 gene. The majority of RA patients carry what researchers call the “shared epitope,” a specific five-amino-acid sequence in an immune protein that was identified in the late 1980s. This genetic variant contributes more to RA risk than all other known non-HLA genetic risk factors combined.
A large analysis covering over 100,000 subjects identified 101 distinct genetic locations associated with RA risk. But having these genes does not guarantee you will develop RA. Environmental triggers, including smoking and hormonal factors, interact with genetic susceptibility to initiate the disease.
Blood Tests Help But Don’t Confirm Alone
Two key blood markers are associated with RA: rheumatoid factor (RF) and anti-CCP antibodies. Anti-CCP antibodies are considered among the most critical biomarkers for diagnosis because they are highly specific to RA. However, not every RA patient tests positive for these markers, especially early in the disease. Some studies show anti-CCP detection rates as low as 53% in patients with symptoms lasting less than one year.
The current diagnostic framework, established in 2010 by the ACR and EULAR, scores patients across four categories: which joints are affected, blood markers (RF and anti-CCP), whether symptoms have lasted more or less than six weeks, and markers of inflammation in the blood (CRP and ESR). A diagnosis requires meeting a threshold across these combined scores, not a single positive test result.
Early Treatment Changes Outcomes
Current guidelines are clear: treatment with disease-modifying drugs should begin as soon as RA is diagnosed. The standard first-line approach is methotrexate, often combined initially with a short course of steroids to control inflammation quickly. If this combination does not produce adequate improvement within three to six months, treatment is escalated based on individual risk factors.
The goal of modern RA treatment is sustained remission, or at minimum, low disease activity. In early disease, remission is a realistic target. In long-standing disease, low disease activity within about six months is the benchmark. This “treat to target” approach has dramatically improved outcomes compared to older strategies that waited for joint damage to appear before intensifying therapy. The earlier the immune-driven inflammation is controlled, the less irreversible joint destruction occurs.